Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

PubMed

Clinical trial design in FDA submissions for neuromodulation devices, 1960-2023: a systematic review and meta-analysis.

PMID : 40542709 ·

B, a, s, s, e, l, , A, l, m, a, r, i, e, ;, , K, e, v, i, n, , P, a, c, h, e, c, o, -, B, a, r, r, i, o, s, ;, , A, n, n, a, , C, a, r, o, l, y, n, a, , G, i, a, n, l, o, r, e, n, c, o, ;, , Y, a, s, m, i, n, , E, l, t, a, w, i, l, ;, , A, l, m, a, , S, a, n, c, h, e, z, ;, , F, e, l, i, p, e, , F, r, e, g, n, i

RevueExpert review of medical devices
Année
PMID40542709

Résumé

Integration of clinical trials into FDA approval processes is essential for ensuring the safety and efficacy of neuromodulation devices. From 1960 to 2023, 125 FDA-approved neuromodulation records corresponding to 109 publications (64 randomized, 45 nonrandomized trials) were identified. Regulatory records and published trial characteristics were reviewed. Safety outcomes were reported in 95.4% of randomized and 82.2% of nonrandomized trials, with serious adverse events in ~ 75% of the studies.

Source officielle

Voir sur PubMed →

Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.

↑